Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study

Archives of Internal Medicine

Volumn 164, Issue 18, 2004, Pages 2051-2057

  Serebruany, Victor L ^d,l   Midei, Mark G ^e   Malinin, Alex I ^d   Oshrine, Benjamin R ^d   Lowry, David R ^e   Sane, David C ^f   Tanguay, Jean François ^g   Steinhubl, Steven R ^a,h   Berger, Peter B ⁱ   O'Connor, Christopher M ^b,i   Hennekens, Charles H ^c,j,k  

^a Brisol Myers Squibb/Sanofi ^*

^b BRISTOL MYERS SQUIBB   (United States)

^c PFIZER INC   (United States)

^d HeartDrug Research   (United States)

^e Midatlantic Cardiovasc Associates   (United States)

^f WAKE FOREST UNIVERSITY   (United States)

^g MONTREAL HEART INSTITUTE   (Canada)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF MIAMI   (United States)

^k Agatston Research Institute   (United States)

^l Osler Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ATORVASTATIN; BIOLOGICAL MARKER; CLOPIDOGREL; FLUINDOSTATIN; G PROTEIN COUPLED RECEPTOR; HEPARIN; HIRUDIN; MEVINOLIN; PRAVASTATIN; PROTEINASE ACTIVATED RECEPTOR 1; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; THROMBOCYTE; THROMBOCYTE AGGREGATION;

AGED; ANTICHOLESTEREMIC AGENTS; BLOOD PLATELETS; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY STENOSIS; DRUG INTERACTIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PYRROLES; STENTS; TICLOPIDINE;

EID: 6344226832     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.18.2051     Document Type: Article

References (31)

1. Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30:1288-1295.
2. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet. 1996;348:1329-1339.
3. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
4. Steinhubl SR, Berger PB, Mann Jr III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA. 2002;288:2411-2420.
5. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
6. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:1660-1661.
7. Serruys PW, de Feyter P, Macaya C, et al, for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287:3215-3222.
8. Eidelman RS, Lamas GA, Hennekens CH. The new National Cholesterol Education Program guidelines: clinical challenges for more widespread therapy of lipids to treat and prevent coronary heart disease. Arch Intern Med. 2002;162:2033-2036.
9. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A- reductase inhibitors (statins). Eur J Clin Pharm. 2001;57:357-364.
10. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-37.
11. Serebruany VL, Malinin AI, Callahan KP, et al. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis. 2001;159:239-241.
12. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol. 2003;92:285-288.
13. Saw J, Steinhubl SR, Berger PP, et al. Lack of adverse clopidogrel-atorvastatin interactions from secondary analyses of a randomized placebo-controlled clopidogrel trial. Circulation. 2003;108:921-924.
14. Serebruany VL, Steinhubl SR, Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? a research question formulated but not yet adequately tested [editorial]. Circulation. 2003;107:1568-1569.
15. Ruggeri ZM. New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994;31:229-239.
16. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195-202.
17. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999;99:620-625.
18. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci. 1993;677:293-308.
19. Serebruany VL, Gurbel PA. The relations of major platelet receptor expression during myocardial infarction: monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Thromb Haemost. 1999;81:314-316.
20. Sotiriou CG, Cheng JW. Beneficial effects of statins in coronary artery disease beyond lowering cholesterol. Ann Pharmacother. 2000;34:1432-1439.
21. Sanguigni V, Pignatelli P, Caccese D, et al. Increased superoxide anion production by platelets in hypercholesterolemic patients. Thromb Haemost. 2002;87:796-801.
22. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;10:2442-2449.
23. Tannous M, Cheung R, Virgini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost. 1999;82:1390-1394.
24. Puccetti L, Pasqui AL, Pastorelli M, et al. Time-dependent effect of statins on platelet function in hypercholesterolaemia. Eur J Clin Invest. 2002;32:901-908.
25. Olvotti L, Ghiglotti G, Spallarossa P, et al. High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. Blood Coagul Fibrinolysis. 2002;13:315-322.
26. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21:1712-1719.
27. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
28. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343-370.
29. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P4503A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
30. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887.
31. Puccetti L, Bruni F, Bova G, et al. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 2001;11:378-387.